title: Management of idiopathic pulmonary fibrosis.
abstract: Idiopathic pulmonary fibrosis (IPF) is a deadly progressive lung disease without an effective standard treatment approach. Because of the complexity and uncertainties of IPF treatment, therapeutic decisions need to be tailored to the individual patient, after discussing the potential benefits and pitfalls. Pirfenidone has been approved for the treatment of IPF in many countries, but is not recommended as a first-choice therapy by current guidelines because of the lack of a definite efficacy. Randomized controlled trials represent a valid choice for patients with IPF, and their completion is important in improving both survival and quality of life.
authors.affiliation: Center for Rare Lung Diseases, Department of Oncology, Hematology and Respiratory Diseases, University Hospital Policlinico of Modena, Modena, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Cerri
authors.forename: Paolo
authors.initials: P
authors.lastname: Spagnolo
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Luppi
authors.forename: Luca
authors.initials: L
authors.lastname: Richeldi
mesh_terms: D000208:Acute Disease; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D002908:Chronic Disease; D015897:Comorbidity; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D007155:Immunologic Factors / Q000627:therapeutic use*; D016040:Lung Transplantation; D058628:Myofibroblasts / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D005343:Fibrinolytic Agents; D007155:Immunologic Factors